Skip to main content
| News

Clinerion launches patient information platform

10.11.2022

Basel-based Clinerion is introducing its machine learning platform. It comprises a global network of hospitals and enables researchers to recognize patterns in large groups of anonymized patient data. It should also make it easier for life science companies to recruit participants for studies.

Clinerion, a global data technology service provider with headquarters in Basel, is bringing its machine learning platform to market. It is linked to a global network of hospitals that provide anonymized electronic patient information, called real-world data, based on their privacy policies. In a press release, Clinerion states that there will be access to 425 million patients in 24 countries. Clinerion has developed its federated machine learning platform together with the Swiss innovation agency Innosuisse, the Bern University of Applied Sciences, and the University of Zurich.

There are two goals for this platform: firstly, it should enable researchers to perform sophisticated analyses and recognize patterns for various illnesses. For example, this would enable high-risk patients to be identified before reaching a critical condition and could be used to find undiagnosed individuals with rare illnesses. Researchers could train models using local data and further optimize them with models from other locations. This would expedite clinical research.

More efficient and efficace

Secondly, the platform aims to “radically” improve the efficiency and efficacy of clinical trial recruitment regarding data-based protocol optimization, location feasibility assessments, and patient screening in real time. Furthermore, it makes it easier for partnering hospitals to participate in these studies.

CEO of Clinerion Barış Erdoğan commented: “Personalized medicine, diversity and inclusion, and rare disease treatment will all benefit from this innovative new technology platform.”

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Gamma Technologies acquires ProFEMAG portfolio
Advanced Manufacturing/AI, Basel Area Business & Innovation, ICT, Innovation, Invest

Gamma Technologies acquires ProFEMAG portfolio

The Basel-based firm ProFEMAG AG has sold its FEMAG software for electrical machine applications to Gamma Technologies. The company based...

Read More
Databaum establishes headquarters in Basel
Basel Area Business & Innovation, ICT, Innovation, Invest, Life Sciences / biotech

Databaum establishes headquarters in Basel

Databaum is establishing its headquarters in Basel and plans to grow from its location there. The startup provides the agricultural...

Read More
Clinerion launches patient information platform
Basel Area Business & Innovation, Digital Health, ICT, Innovation, Invest, Life Sciences / biotech

Clinerion launches patient information platform

Basel-based Clinerion is introducing its machine learning platform. It comprises a global network of hospitals and enables researchers to recognize...

Read More
New innovation campus opens in the Basel Area
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech, Switzerland Innovation Park

New innovation campus opens in the Basel Area

The Main Campus of the Switzerland Innovation Park Basel Area was officially opened on October 29. In his speech, Federal...

Read More
Sumitovant acquires all shares in Myovant
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Sumitovant acquires all shares in Myovant

Sumitovant is in the process of making Basel-based Myovant Sciences a wholly owned subsidiary by acquiring a 100 percent shareholding...

Read More
VectivBio raises 125 million US dollars in stock sale
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

VectivBio raises 125 million US dollars in stock sale

VectivBio has announced the closing of the subscription offer for 16,700,000 ordinary shares. The Basel-based biotechnology firm has generated gross...

Read More
1 2 3 29

Do you have a question? We'd like to hear from you.